drugset / Trial / NCT03669250
CVN058 Effect on Mismatch Negativity in Schizophrenics
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a phase 1, double-blind, placebo-controlled, 3 period cross-over study to evaluate CVN058 target engagement by measuring auditory evoked potential mismatch negativity (MMN) downstream to 5-hydroxytryptamine receptor 3 (5-HT3) as a pharmacodynamic (PD) marker.
Timeline
- Start
- 2018-11-09
- Primary completion
- 2020-03-06
- Completion
- 2020-03-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TAK-058 | Unknown | 15 mg | Oral |
| Comparator | TAK-058 | Unknown | 75 mg | Oral |
| Comparator | TAK-058 | Unknown | 150 mg | Oral |